By Joe Hoppe
BiVictriX Therapeutics said Monday that it has received positive final data from a second in vivo efficacy study of its lead clinical candidate, BVX001, an antibody for treating acute myeloid leukemia.
The cancer-therapies company said that at day 28 of the study, BVX001 induced highly statistically-significant tumor regressions of 97%. The results expand upon positive interim data from the same study that showed tumor regressions of 89% at day 18.
The company said the U.S. Patent and Trademark Office has issued a notice of allowance for an initial broad patent for the drug in the U.S.
The study was to assess the anti-tumor responses of BVX001 dosed twice weekly in a more challenging setting where tumors were administered at a large size. It expects the patent claims will be granted in the U.S. within the coming months.
“These results will form part of the comprehensive preclinical data package that we are building to pave the way for advancing BVX001 into human trials,” Chief Executive Tiffany Thorn said.
Write to Joe Hoppe at [email protected]
Read the full article here
